142 related articles for article (PubMed ID: 31940465)
1. Conversion to positive latent tuberculosis infection status is low in patients with hidradenitis suppurativa taking biologic medications.
Ellis A; Khanna U; Galadari A; Fernandez AP
J Am Acad Dermatol; 2020 Jul; 83(1):246-248. PubMed ID: 31940465
[No Abstract] [Full Text] [Related]
2. Low rate of conversion to positive tuberculosis status among patients with psoriasis on biologic therapies: A retrospective study from a US academic medical center.
Daniel VT; Blankenship KC; Daly RF; Tkachenko E; Morss-Walton PC; Levin NA
J Am Acad Dermatol; 2021 Mar; 84(3):830-833. PubMed ID: 33010315
[No Abstract] [Full Text] [Related]
3. Prevalence of antinuclear antibodies in hidradenitis suppurativa.
Mulani S; McNish S; Jones D; Shanmugam VK
Int J Rheum Dis; 2018 May; 21(5):1018-1022. PubMed ID: 29878616
[TBL] [Abstract][Full Text] [Related]
4. Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience.
Bettoli V; Manfredini M; Calamo G; Forconi R; Bencivelli D; Mantovani L; Pellacani G; Corazza M
Dermatol Ther; 2018 Nov; 31(6):e12737. PubMed ID: 30295378
[No Abstract] [Full Text] [Related]
5. The prevalence of latent tuberculosis in dermatology patients on immunosuppressant therapy in New Orleans, Louisiana: A retrospective record review.
Elliott E; Sarac R; Foutouhi S; Maghfour J; Patel N; Martel J; Murina A
J Am Acad Dermatol; 2020 May; 82(5):1242-1243. PubMed ID: 31866262
[No Abstract] [Full Text] [Related]
6. Screening for latent tuberculosis infection among patients with rheumatoid arthritis in the era of biologics and targeted synthetic disease-modifying anti-rheumatic drugs in India, a high-burden TB country: The importance of Mantoux and Quantiferon-TB Gold tests.
Malaviya AN; Aggarwal VK; Rawat R; Baghel S; Thakran R; Zaheer Q; Garg S; Kapoor S
Int J Rheum Dis; 2018 Aug; 21(8):1563-1571. PubMed ID: 29345081
[TBL] [Abstract][Full Text] [Related]
7. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
[TBL] [Abstract][Full Text] [Related]
8. Biological agents and tuberculosis: risk estimates and screening strategies.
Dobler CC
Int J Rheum Dis; 2015 Mar; 18(3):264-7. PubMed ID: 25923605
[No Abstract] [Full Text] [Related]
9. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
[TBL] [Abstract][Full Text] [Related]
10. Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient.
Rodríguez-Jiménez P; Mir-Viladrich I; Chicharro P; Solano-López G; López-Longo FJ; Taxonera C; Sánchez-Martínez P; Martínez-Lacasa X; García-Gasalla M; Dorca J; Arias-Guillén M; García-García JM; Dauden E
Actas Dermosifiliogr (Engl Ed); 2018 Sep; 109(7):584-601. PubMed ID: 29871738
[TBL] [Abstract][Full Text] [Related]
11. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa.
Turk D; Vellaichamy G; Lyons AB; Parks-Miller A; Nelson T; Meysami A; Hamzavi IH
Int J Dermatol; 2020 Mar; 59(3):e73-e74. PubMed ID: 31633193
[No Abstract] [Full Text] [Related]
13. Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?
Abdalla T; Lowes MA; Kaur N; Micheletti RG; Steinhart AH; Alavi A
Am J Clin Dermatol; 2021 Mar; 22(2):139-147. PubMed ID: 33398848
[TBL] [Abstract][Full Text] [Related]
14. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
[TBL] [Abstract][Full Text] [Related]
15. Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: a combined approach by QuantiFERON-TB Gold and tuberculin skin tests.
Prignano F; Bartoloni A; Bartalesi F; Gori A; Ricceri F; Cavallo A; Attala L; Mantella A
Int J Dermatol; 2014 Aug; 53(8):e372-4. PubMed ID: 24898978
[No Abstract] [Full Text] [Related]
16. Prevalence of positive QuantiFERON gold in-tube testing in hidradenitis suppurativa.
Boortalary T; Misra K; McNish S; Jones D; Shanmugam VK
J Dermatolog Treat; 2018 Sep; 29(6):637-640. PubMed ID: 29325465
[TBL] [Abstract][Full Text] [Related]
17. Concurrent anticytokine biologics for the management of severe hidradenitis suppurativa: are they safe and effective?
Naik HB; McGinness A; Shinkai K
Cutis; 2018 Mar; 101(3):163;164;176. PubMed ID: 29718020
[No Abstract] [Full Text] [Related]
18. Successful use of guselkumab in the treatment of severe hidradenitis suppurativa.
Kearney N; Byrne N; Kirby B; Hughes R
Clin Exp Dermatol; 2020 Jul; 45(5):618-619. PubMed ID: 32068912
[No Abstract] [Full Text] [Related]
19. Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents.
Klein M; Jarosová K; Forejtová S; Bečvář R; Sedová L; Pavelka K; Simková G; Svobodová R; Hviscová K; Mann H; Půtová I; Vencovský J
Clin Exp Rheumatol; 2013; 31(1):111-7. PubMed ID: 23101473
[TBL] [Abstract][Full Text] [Related]
20. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
